EX-10.5
from 8-K
8 pages
Reference Is Made to That Certain Business Combination Agreement, Dated as of October 17, 2022 (As Amended, the “Business Combination Agreement”) by and Between European Biotech Acquisition Corp., a Cayman Islands Exempted Company (Including Any Successor Entity Thereto, “EBAC”) and Oculis SA, a Public Limited Liability Company (Société Anonyme) Incorporated and Existing Under the Laws of Switzerland (The “Company”). Any Capitalized Term Used but Not Defined Herein Will Have the Meanings Ascribed Thereto in the Business Combination Agreement. as of the Date of This Sponsor Letter Agreement, Lsp Sponsor EBAC B.V., a Dutch Limited Liability Company (“Sponsor”) Is the Record and Beneficial Owner of 3,188,696 Shares of EBAC Class B Common Stock (The “Founder Shares”). for Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, Sponsor, the Company and EBAC Agree as Follows: 1. Redemption and Voting
12/34/56
